Rifapentine is a cyclopentyl derivative of rifampin. It is a drug in the class rifamycins. The US CDC's Tuberculosis Trials Consoritum (TBTC)'s published results of a 4-month rifapentine-based regimen containing moxifloxacin as noninferior to the standard 6-month regimen in the treatment of tuberculosis.
Rifapentine has been approved by stringent regulatory authorities since 1999. In 2014, it was approved for use in treating latent TB. It is under continued investigation in Phase 2 and Phase 3 clinical trials alongside other drugs/drug candidates in novel TB drug regimens for multiple forms of TB.